+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Leptomeningeal Metastases - Market Insight, Epidemiology and Market Forecast -2032

  • PDF Icon

    Report

  • 120 Pages
  • January 2022
  • Region: Global
  • DelveInsight
  • ID: 5524479
UP TO OFF until Dec 31st 2024
This "Leptomeningeal Metastases- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Leptomeningeal Metastases market report provides current treatment practices, emerging drugs, Leptomeningeal Metastases market share of the individual therapies, current and forecasted Leptomeningeal Metastases market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Leptomeningeal Metastases treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Leptomeningeal Metastases Disease Understanding and Treatment Algorithm


The Leptomeningeal Metastases market report gives a thorough understanding of the Leptomeningeal Metastases by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Leptomeningeal Metastases.

Treatment


It covers the details of conventional and current medical therapies available in the Leptomeningeal Metastases market for the treatment of the condition. It also provides Leptomeningeal Metastases treatment algorithms and guidelines in the United States, Europe, and Japan.

Leptomeningeal Metastases Epidemiology


The Leptomeningeal Metastases epidemiology division provide insights about historical and current Leptomeningeal Metastases patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Leptomeningeal Metastases epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Leptomeningeal Metastases Epidemiology


The epidemiology segment also provides the Leptomeningeal Metastases epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Leptomeningeal Metastases Drug Chapters


Drug chapter segment of the Leptomeningeal Metastases report encloses the detailed analysis of Leptomeningeal Metastases marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Leptomeningeal Metastases clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Leptomeningeal Metastases treatment.

Leptomeningeal Metastases Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Leptomeningeal Metastases treatment.

Leptomeningeal Metastases Market Outlook


The Leptomeningeal Metastases market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Leptomeningeal Metastases market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Leptomeningeal Metastases market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Leptomeningeal Metastases market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Leptomeningeal Metastases market in 7MM.

The United States Market Outlook


This section provides the total Leptomeningeal Metastases market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Leptomeningeal Metastases market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Leptomeningeal Metastases market size and market size by therapies in Japan is also mentioned.

Leptomeningeal Metastases Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Leptomeningeal Metastases market or expected to get launched in the market during the study period 2019-2032. The analysis covers Leptomeningeal Metastases market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Leptomeningeal Metastases Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Leptomeningeal Metastases key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Leptomeningeal Metastases emerging therapies.

Reimbursement Scenario in Leptomeningeal Metastases


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Leptomeningeal Metastases domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Leptomeningeal Metastases market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Leptomeningeal Metastases Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Leptomeningeal Metastases, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Leptomeningeal Metastases epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Leptomeningeal Metastases are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Leptomeningeal Metastases market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Leptomeningeal Metastases market

Report Highlights

  • In the coming years, Leptomeningeal Metastases market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Leptomeningeal Metastases R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Leptomeningeal Metastases. Launch of emerging therapies will significantly impact the Leptomeningeal Metastases market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Leptomeningeal Metastases
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Leptomeningeal Metastases Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Leptomeningeal Metastases Pipeline Analysis
  • Leptomeningeal Metastases Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Leptomeningeal Metastases Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Leptomeningeal Metastases Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Leptomeningeal Metastases Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Leptomeningeal Metastases market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Leptomeningeal Metastases total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Leptomeningeal Metastases market size during the forecast period (2019-2032)?
  • At what CAGR, the Leptomeningeal Metastases market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Leptomeningeal Metastases market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Leptomeningeal Metastases market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Leptomeningeal Metastases?
  • What is the historical Leptomeningeal Metastases patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Leptomeningeal Metastases in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Leptomeningeal Metastases?
  • Out of all 7MM countries, which country would have the highest prevalent population of Leptomeningeal Metastases during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Leptomeningeal Metastases treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Leptomeningeal Metastases in the USA, Europe, and Japan?
  • What are the Leptomeningeal Metastases marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Leptomeningeal Metastases?
  • How many therapies are developed by each company for Leptomeningeal Metastases treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Leptomeningeal Metastases treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Leptomeningeal Metastases therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Leptomeningeal Metastases and their status?
  • What are the key designations that have been granted for the emerging therapies for Leptomeningeal Metastases?
  • What are the global historical and forecasted market of Leptomeningeal Metastases?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Leptomeningeal Metastases market
  • To understand the future market competition in the Leptomeningeal Metastases market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Leptomeningeal Metastases in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Leptomeningeal Metastases market
  • To understand the future market competition in the Leptomeningeal Metastases market

Table of Contents

1. Key Insights2. Report Introduction
3. Leptomeningeal metastases Market Overview at a Glance
3.1. Market Share (%) Distribution of Leptomeningeal metastases in 2018
3.2. Market Share (%) Distribution of Leptomeningeal metastases in 2030
4. Executive Summary of Leptomeningeal Metastases
4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Risk factors of Leptomeningeal metastases
6.3. Signs and Symptoms of Leptomeningeal metastases
6.4. Pathophysiology of Leptomeningeal metastases
6.5. Biomarkers
6.6. Complications
7. Diagnosis of Leptomeningeal metastases
7.1. Diagnostic Algorithm
7.2. Diagnostic Tests
7.2.1. Cerebral Spinal Fluid Cytology
7.2.2. Lumbar puncture
7.2.3. Magnetic Resonance Imaging (MRI)
7.3. Differential diagnosis
8. Treatment of Leptomeningeal Metastases
8.1. Treatment Algorithm
8.2. Symptomatic
8.3. Surgery
8.4. Radiation therapy
8.5. Chemotherapy
8.5.1. Intrathecal Chemotherapy
8.5.2. Systemic Chemotherapy
9. Diagnosis and Treatment Guidelines
9.1. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of patients with leptomeningeal metastasis from solid tumors (2017)
9.2. National Comprehensive Council Network (NCCN) Guidelines (2021)
10. Conclusion
11. Epidemiology and Patient Population
11.1. Key Findings
11.2. Epidemiology of Leptomeningeal Metastases
11.3. Epidemiology Scenario
11.3.1. Total Incident Cases of different cancer types
11.3.2. Total Diagnosed Cases of Leptomeningeal Metastases
11.3.3. Total Cancer-specific Leptomeningeal Metastases Cases
11.3.4. Total Treated Cases of Leptomeningeal Metastases
12. Patient Journey of Leptomeningeal Metastases13. Key Endpoints in Leptomeningeal Metastases Clinical Trials
14. Emerging Therapies
14.1. Key Cross
14.2. Rhenium-186 NanoLiposome (186RNL): Plus Therapeutics
14.2.1. Product Description
14.2.2. Other Developmental Activities
14.2.3. Clinical Development
14.3. AZD1390: AstraZeneca
14.3.1. Product Description
14.3.2. Clinical Developmental Activities
14.4. Paclitaxel trevatide (ANG1005): Angiochem
14.4.1. Product Description
14.4.2. Other Development Activities
14.4.3. Clinical Developmental Activities
14.5. Omburtamab: Y-mAbs Therapeutics
14.5.1. Product Description
14.5.2. Other development activities
14.5.3. Clinical Development
14.5.4. Safety and Efficacy
15. Leptomeningeal Metastases (LM): 7 Major Market Analysis
15.1. Key Findings
15.2. Market Outlook
15.3. Market Size of Leptomeningeal metastases
15.3.1. Total Market Size of Leptomeningeal metastases
15.3.2. Market Size of Leptomeningeal metastases by Therapies
16. Market Access and Reimbursement17. KOL Views18. Market Drivers19. Market Barriers20. SWOT Analysis21. Unmet Needs
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. Capabilities24. Disclaimer25. About the Publisher
List of Tables
Table 1: Summary of Leptomeningeal Metastases, Epidemiology (2019-2032)
Table 2: Total Incident Cases of different cancer types* (in Millions) (2019-2032)
Table 3: Total Diagnosed Cases of Leptomeningeal Metastases (in Thousands) (2019-2032)
Table 4: Total Cancer-specific Leptomeningeal Metastases Cases (in Thousands) (2019-2032)
Table 5: Total Treated Cases of Leptomeningeal Metastases (in Thousands) (2019-2032)
Table 6: Drug Key Cross of emerging drugs under development for Leptomeningeal Metastases
Table 7: Rhenium-186 NanoLiposome (186RNL), Clinical Trial Description, 2022
Table 8: AZD1390: AstraZeneca, Clinical Trial Description, 2022
Table 9: Paclitaxel trevatide, Clinical Trial Description, 2022
Table 10: Omburtamab, Clinical Trial Description, 2022
Table 11: 7MM Market Size of Leptomeningeal metastases in USD Million (2019-2032)
Table 12: 7MM Market Size of Leptomeningeal metastases by Therapies in USD Million (2019-2032)
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 1: Understanding of Leptomeningeal metastases
Figure 2: Sign and Symptoms of Leptomeningeal metastases
Figure 3: Pathophysiology of Leptomeningeal metastases
Figure 4: Diagnostic Algorithm of Leptomeningeal metastases
Figure 5: Diagnosis of Leptomeningeal metastases
Figure 6: Lumbar puncture of Leptomeningeal metastases
Figure 7: MRI of Leptomeningeal metastases
Figure 8: Treatment Algorithm of Leptomeningeal metastases in patients with breast cancer
Figure 9: Ommaya catheter
Figure 10: NCCN Guidelines
Figure 11: Total Incident Cases of different cancer types* in the 7MM (2019-2032)
Figure 12: Total Diagnosed Cases of Leptomeningeal Metastases in the 7MM (2019-2032)
Figure 13: Total Cancer-specific Leptomeningeal Metastases Cases in the 7MM (2019-2032)
Figure 14: Total Treated Cases of Leptomeningeal Metastases in the 7MM (2019-2032)
Figure 15: Market Size of Leptomeningeal metastases in the 7MM USD Million (2019-2032)
Figure 16: 7MM Market Size of Leptomeningeal metastases by Therapies in USD Million (2019-2032)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Plus Therapeutics
  • AstraZeneca
  • Angiochem
  • Y-mAbs Therapeutics